<DOC>
	<DOCNO>NCT02011113</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety pomalidomide combination dexamethasone subject relapse refractory multiple myeloma .</brief_summary>
	<brief_title>Japanese Phase 2 Study Evaluate Efficacy Safety Pomalidomide Subjects With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Must ≥ 20 year age time sign informed consent document . 2 . The subject must understand voluntarily sign informed consent document study relate assessments/procedures conduct . 3 . Must able adhere study visit schedule protocol requirement . 4 . Have document diagnosis multiple myeloma relapse refractory disease . Subjects must receive least 2 prior therapy . Subjects must relapse achieve least stable disease least one cycle treatment least one prior regimen develop progressive disease ( PD ) . Subjects must also document evidence progressive disease ( PD ) within 60 day ( measure end last cycle ) complete treatment last antimyeloma drug regimen use prior study entry ( refractory disease ) . 5 . Subjects must undergo prior treatment least 2 cycle lenalidomide least 2 cycle bortezomib ( either separate regimen within regimen ) . 6 . Subjects must document diagnosis multiple myeloma measurable disease ( serum Mprotein ≥ 0.5 g/dL urine Mprotein ≥ 200 mg/24 hour ) . 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 . 8.Must agree comply pomalidomide Pregnancy Prevention Risk Management Plan . 1 . Pregnant breastfeeding female 2 . Hypersensitivity thalidomide , lenalidomide , dexamethasone 3 . ≥ Grade 3 rash prior thalidomide lenalidomide therapy 4 . Subjects unable unwilling undergo antithrombotic prophylactic treatment eligible participate study 5 . Any following laboratory abnormality : Absolute neutrophil count &lt; 1,000/µL Platelet count &lt; 75,000/µL subject &lt; 50 % bone marrow nucleate cell plasma cell ; platelet count &lt; 30,000/µL subject ≥ 50 % bone marrow nucleate cell plasma cell Creatinine Clearance &lt; 45 mL/min accord CockcroftGault formula CockcroftGault estimation Creatinine Clearance : Corrected serum calcium &gt; 14 mg/dL ( &gt; 3.5 mmol/L ) Hemoglobin &lt; 8 g/dL ( &lt; 4.9 mmol/L ; prior Red blood cell transfusion recombinant human erythropoietin use permit ) Serum glutamic oxaloacetic transaminase ( SGOT ) /aspartate aminitransferase ( AST ) serum glutamic pyruvic transaminase ( SGPT ) /alanine aminotransferase ( ALT ) &gt; 3.0 x upper limit normal ( ULN ) Serum total bilirubin &gt; 2.0 mg/dL ( 34.2 μmol/L ) ; ≥ 3.0 x upper limit normal ( ULN ) subject hereditary benign hyperbilirubinemia . 6 . Subjects one following : Congestive heart failure ( New York Heart Association Class III IV ) Myocardial infarction within 12 month prior start study treatment Unstable poorly control angina pectoris , include Prinzmetal variant angina pectoris 7 . Peripheral neuropathy ≥ Grade 2 . 8 . Prior history malignancy , multiple myeloma , unless subject free disease ≥ 5 year . Exceptions include follow : Basal Squamous cell carcinoma skin Carcinoma situ cervix breast Incidental histologic find prostate cancer ( TNM stage T1a T1b ) 9 . Known infection human immunodeficiency virus ( HIV ) antibody positive , hepatitis B virus surface antigen ( HBsAg ) positive hepatitis C virus antibody ( HCVAb ) positive . If negative hepatitis B virus surface antigen ( HBsAg ) hepatitis B core antibody ( HBcAb ) and/or hepatitis B surface antibody ( HBsAb ) positive status , hepatitis B virus DNA test perform positive subject exclude . 10 . Incidence gastrointestinal disease may significantly alter absorption pomalidomide . 11 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study . 12 . Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study . 13 . Any condition confound ability interpret data study . 14 . Previous therapy pomalidomide . 15 . Use investigational agent within 28 day 5 halflives ( whichever longer ) treatment . 16 . Subjects condition require chronic steroid immunosuppressive treatment , rheumatoid arthritis , multiple sclerosis , lupus , likely need additional steroid immunosuppressive treatment addition study treatment . Includes subject receive corticosteroid ( &gt; 10 mg/day prednisone equivalent ) within 3 week prior enrollment . 17 . Subjects receive follow within last 14 day initiation study treatment : Plasmapheresis Major surgery ( kyphoplasty consider major surgery ) Radiation therapy Use antimyeloma drug therapy . 18 . Subjects receive allogeneic bone marrow allogeneic peripheral blood stem cell transplant le 12 month prior initiation study treatment discontinue immunosuppressive treatment least 4 week prior initiation study treatment currently dependent treatment . 19 . Subjects plan eligible stem cell transplant .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Pomalidomide ,</keyword>
	<keyword>CC-4047 ,</keyword>
	<keyword>Dexamethasone ,</keyword>
	<keyword>Relapsed refractory multiple myeloma ,</keyword>
	<keyword>phase 2</keyword>
</DOC>